Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Denali Therapeutics Inc (NQ: DNLI )

31.70 -0.97 (-2.97%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 517,946
Open 31.92
Bid (Size) 30.07 (1)
Ask (Size) 33.37 (1)
Prev. Close 32.67
Today's Range 31.52 - 32.81
52wk Range 20.24 - 39.43
Shares Outstanding 121,640,069
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023
 
Via Benzinga
Expert Ratings for Denali Therapeutics
 
Via Benzinga

Performance

YTD
+14.73%
+14.73%
1 Month
+14.73%
+14.73%
3 Month
+3.49%
+3.49%
6 Month
-5.09%
-5.09%
1 Year
-6.79%
-6.79%

More News

Read More
Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in Multiple Sclerosis by Sanofi
From Denali Therapeutics Inc.
Via Globe NewsWire
Denali Therapeutics Announces Key Anticipated 2023 Milestones for Its Therapeutic Portfolio for Neurodegeneration and Lysosomal Storage Diseases
From Denali Therapeutics Inc.
Via Globe NewsWire
Benzinga's Top Ratings Upgrades, Downgrades For December 5, 2022
Via Benzinga
Denali Therapeutics Announces DNL343 Interim Phase 1b Data in ALS and Entry into the HEALEY ALS Platform Trial
From Denali Therapeutics Inc.
Via Globe NewsWire
Denali Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
From Denali Therapeutics Inc.
Via Globe NewsWire
Why Denali Therapeutics' Stock Rose 6.6% on Wednesday
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2022
Via Benzinga
Denali Therapeutics Announces Phase 1/2 Study Single Dose Healthy Volunteer Data with TAK-594/DNL593 (PTV:PGRN) and Progression to Enrolling Participants with FTD-GRN
From Denali Therapeutics Inc.
Via Globe NewsWire
Denali Therapeutics Announces Closing of a $316 Million Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Denali Therapeutics Inc.
Via Globe NewsWire
Denali Therapeutics Announces Pricing of $275 Million Public Offering of Common Stock
From Denali Therapeutics Inc.
Via Globe NewsWire
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
Denali Therapeutics Announces Proposed Offering of Common Stock
From Denali Therapeutics Inc.
Via Globe NewsWire
Biogen and Denali Therapeutics Announce Initiation of the Phase 3 LIGHTHOUSE Study in Parkinson’s Disease Associated with LRRK2 Pathogenic Mutations
From Denali Therapeutics Inc.
Via Globe NewsWire
Netflix, Biogen And Other Big Gainers From Wednesday
Via Benzinga
Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday
Via Benzinga
R&D Efforts for Central Nervous System (CNS) Therapeutics Have Resulted in Hopeful Novel Drug-Delivery Solutions
Via FinancialNewsMedia
Why Prothena Corporation Shares Are Trading Higher By 76%, Here Are 53 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Rising Cases Of Mental Health Disorders of Stress, Anxiety & Addiction Fueling Need for Central Nervous System Therapeutics
Via FinancialNewsMedia
Exposures COVID-19
Benzinga's Top Ratings Upgrades, Downgrades For June 23, 2022
Via Benzinga
Revenues From Treatment of Rare Neurological Disorders Worldwide Are Poised to Surpass $12 Billion in 2026
Via FinancialNewsMedia
4 Undervalued Biotech Stocks to Add to Your Buy List
Via InvestorPlace
AbbVie Stock Breaks Its Stride As Key Executive Departs For Flagship
Via Investor's Business Daily
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.